ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Medicare"

  • Abstract Number: 129 • 2017 ACR/ARHP Annual Meeting

    Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients

    Jeffrey R. Curtis1, Kerri Ford2, Lang Chen3, Huifeng Yun3 and Fenglong Xie4, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2Crescendo Bioscience Inc., South San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The multi-biomarker disease activity (MBDA) score is a validated test used to assess disease activity for patients with rheumatoid arthritis (RA). How it is…
  • Abstract Number: 136 • 2017 ACR/ARHP Annual Meeting

    Prevalence of Rheumatoid Arthritis and Associated Comorbidities in the 2011-2015 Medicare Population

    Suying Li, Julia T. Molony, Yi Peng, Kimberly M. Nieman and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting about 1.5 million adults in the US (Helmick et al., 2008). Patients with RA have…
  • Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting

    Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study

    Seoyoung C. Kim1, Tuhina Neogi2, Eun Ha Kang3, Jun Liu4, Rishi J. Desai5, MaryAnn Zhang6 and Daniel H. Solomon7, 1Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 2Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 3Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…
  • Abstract Number: 128 • 2016 ACR/ARHP Annual Meeting

    Call to Action: Cardiovascular Comorbidities in Medicare Rheumatology Beneficiaries

    Gurjit S. Kaeley1 and Sunita Dodani2, 1University of Florida, Ponte Vedra Beach, FL, 2Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL

    Background/Purpose: Cardiovascular (CV) manifestations of Rheumatological inflammatory diseases have become increasingly recognized, and, in some patients, might even constitute the initial presentation of a Rheumatological…
  • Abstract Number: 145 • 2016 ACR/ARHP Annual Meeting

    Reduction in Musculoskeletal Ultrasound (MSK-US) Payments in 2014: Effects & Consequences

    Gurjit S. Kaeley1 and Sunita Dodani2, 1Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 2Epidemiology, University of Florida, College of Medicine & College of Public Health and Health Professions, Gainesville, Jacksonville, FL

      Background/Purpose: Rapid rise in the use of diagnostic and interventional MSK-US within the Medicare population between 2011 and 2013 has been documented amongst non-radiology…
  • Abstract Number: 1255 • 2016 ACR/ARHP Annual Meeting

    Medicare Part B Utilization By Rheumatology Health Care Providers As Related to Population Demographics from 2013

    Sreelakshmi Panginikkod1, David T Liss2, Venu Pararath Gopalakrishnan1, Pratyusha Bollimunta1, Andriy Havrylyan1, Farah Faridi1 and Manish Jain3, 1Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, 2Northwestern University, Chicago, IL, 3Rheumatology, Presence Saint Francis Hospital, Evanston, IL

    Background/Purpose: In 2015, the Center for Medicare and Medicaid Services released claims data on payments to over 950,000 health care providers paid through Medicare Part…
  • Abstract Number: 925 • 2015 ACR/ARHP Annual Meeting

    Musculoskeletal Ultrasound (MSK-US): Innovation or Overutilization?

    Gurjit S. Kaeley1, Dale Kraemer2, Carmen Smotherman3 and Sunita Dodani4, 1Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 2Center for Health Equity and Quality Research, Department of Neurology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 3Center for Health Equity and Quality Research,, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 4Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL

    Background/Purpose: MSK-US use has risen in the USA with recent disturbing findings suggesting greater utilization of interventional ultrasound by non-noradiologists compared to Radiologists. (1) This…
  • Abstract Number: 1268 • 2015 ACR/ARHP Annual Meeting

    Utilization of Viscosupplementation: 2011 – 2013

    Gurjit S. Kaeley1, Myint Thway1 and Sunita Dodani2, 1Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, 2Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL

    Background/Purpose: Viscosupplementation (VS) is approved in the USA as an option for knee osteoarthritis (OA) pain. Recent American Academy of Orthopedic Surgeons (AAOS) guidelines have…
  • Abstract Number: 1910 • 2014 ACR/ARHP Annual Meeting

    Risk of Hypersensitiviy Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics

    Huifeng Yun1, Fenglong Xie2, Lang Chen3, James Lewis4 and Jeffrey R. Curtis5, 1Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Healthcare providers have been alerted to the potential drug hypersensitivity reactions (HSRs, an adverse drug reaction that are uncommon but may be severe and…
  • Abstract Number: 1849 • 2014 ACR/ARHP Annual Meeting

    Risk of Malignancy Among Medicare Psoriasis/Psoriasis Arthritis Patients

    Huifeng Yun1, Kevin L. Winthrop2, Lang Chen3, Wilson Smith4, Benjamin Chan5, Fenglong Xie6, Allison Taylor4 and Jeffrey R. Curtis7, 1Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Oregon Health and Science University, Portland, OR, 6Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose The introduction of biologics has greatly changed the treatment of psoriatic arthritis (PsA) and psoriasis (PsO). However, there are concerns regarding the risk of…
  • Abstract Number: 1070 • 2014 ACR/ARHP Annual Meeting

    Mortality Risk in Patients with Rheumatoid Arthritis Who Develop Non–Hodgkin′s Lymphoma

    Pratibha Nayak1, Zaki Abou Zahr2, Ruili Luo3, Linda Elting3 and Maria E. Suarez-Almazor4, 1General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2Rheumatology, Baylor College of Medicine, Houston, TX, 3The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, 4The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose Patients with rheumatoid arthritis (RA) have greater risk of non-Hodgkin lymphoma (NHL) than the general population. A previous two-center study suggested that the rates…
  • Abstract Number: 1069 • 2014 ACR/ARHP Annual Meeting

    Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study

    Pratibha Nayak1, Ruili Luo2, Linda Elting2 and Maria E. Suarez-Almazor3, 1General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose Comorbidity among cancer patients imposes additional risks for premature mortality. The specific effect of rheumatoid arthritis (RA) on survival among cancer patients is unknown.…
  • Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting

    Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis

    Jinoos Yazdany1, R. Adams Dudley2, Randi Chen3 and Chien-Wen Tseng4, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Medicine, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, 3Pacific Health Research and Education Institute, Honolulu, HI, 4Dept of Family Medicine and Community Health, University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI

    Background/Purpose :  Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA).  We evaluated how well RA drugs…
  • Abstract Number: 204 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population

    E Alemao1, L Wang2, G Lltalien1, O Baser3, H Yuce4 and M Hochberg5, 1Bristol-Myers Squibb, Princeton, NJ, 2STATinMED Research, Dallas, TX, 3STATinMED Research and University of Michigan, Ann Arbor, MI, 4New York City College of Technology (CUNY), Brooklyn, NJ, 5University of Maryland, Baltimore, MD

    Background/Purpose: RA-related hospitalization and surgery (e.g. total joint arthroplasty [TJA]) are important long-term outcomes in RA. While advances in treatment for RA have resulted in…
  • Abstract Number: 2338 • 2013 ACR/ARHP Annual Meeting

    Biologic Switching Rates Among Patients With Rheumatoid Arthritis

    L Rosenblatt1, F Lobo1, P Cockrum2, L Wang3, E Alemao2, O Baser4 and H Yuce5, 1Bristol-Myers Squibb, Plainsboro, NJ, 2Bristol-Myers Squibb, Princeton, NJ, 3STATinMED Research, Dallas, TX, 4STATinMED Research and University of Michigan, Ann Arbor, MI, 5New York City College of Technology (CUNY), Brooklyn, NJ

    Background/Purpose: Treatment guidelines for the management of RA recommend sequential use of biologic therapies, and the majority of patients switch from one anti-TNF agent to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology